4/2
08:50 am
autl
Autolus Therapeutics price target lowered to $10 from $11 at Truist [Yahoo! Finance]
Low
Report
Autolus Therapeutics price target lowered to $10 from $11 at Truist [Yahoo! Finance]
4/2
07:00 am
autl
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/1
09:04 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target lowered by analysts at Truist Financial Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target lowered by analysts at Truist Financial Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.
4/1
07:00 am
autl
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
High
Report
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
3/26
10:01 am
autl
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
Low
Report
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
3/26
10:01 am
autl
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
Low
Report
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
3/24
08:29 am
autl
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval [Yahoo! Finance]
Low
Report
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval [Yahoo! Finance]
3/21
03:17 pm
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target lowered by analysts at Wells Fargo & Company from $8.00 to $6.00. They now have an "overweight" rating on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its price target lowered by analysts at Wells Fargo & Company from $8.00 to $6.00. They now have an "overweight" rating on the stock.
3/20
07:00 am
autl
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
High
Report
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
3/11
05:31 pm
autl
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
Low
Report
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
3/11
05:31 pm
autl
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
Low
Report
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
3/6
07:43 am
autl
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 [Yahoo! Finance]
Low
Report
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 [Yahoo! Finance]
3/6
07:00 am
autl
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
Low
Report
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
3/5
05:31 pm
autl
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
Low
Report
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
3/5
05:31 pm
autl
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
Low
Report
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
3/5
07:42 am
autl
Autolus Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
High
Report
Autolus Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/5
07:00 am
autl
Autolus Therapeutics to Participate in Upcoming Investor Conferences
High
Report
Autolus Therapeutics to Participate in Upcoming Investor Conferences
2/26
07:00 am
autl
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
Low
Report
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
2/25
05:31 pm
autl
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
Low
Report
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
2/25
05:31 pm
autl
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
Low
Report
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
2/18
09:00 am
autl
PDA Releases Points to Consider Number 11 for Plasmids and Vectors in ATMP Production
Low
Report
PDA Releases Points to Consider Number 11 for Plasmids and Vectors in ATMP Production
1/17
07:41 am
autl
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings [Yahoo! Finance]
1/17
07:00 am
autl
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Low
Report
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
1/13
10:58 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
1/13
07:00 am
autl
Autolus Therapeutics Provides Business Updates and 2025 Overview
Low
Report
Autolus Therapeutics Provides Business Updates and 2025 Overview